EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Health utility values in myasthenia gravis: a systematic review of health-related quality of life evidence and estimations for Brazilian economic models

Marisa Santos, Márcia Gisele Santos da Costa, Ligia Fernande Yoshida, Gabriela Ana Kanevsky, Ligia Taveira Engler Raiz Coelho

HTA Journal · 04.08.2026 · 1 (1) · 19-31

DOI: 10.67516/htaj.26.1.19 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift HTA Journal, online erschienen am 04.08.2026. Verfasst von Marisa Santos und 4 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Myasthenia gravis (MG) is a rare autoimmune disease characterized by a neuromuscular disorder that leads to weakness in the limbs, ocular muscles, or respiratory muscles.

Objective

To perform a systematic review of the literature to identify and synthesize evidence on quality of life and utility data among individuals with MG. Methodology: Conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered in PROSPERO (CRD420251137166), this review involved a comprehensive search across Embase, LILACS, MEDLINE, the Cochrane Library, and Google Scholar. Eligible studies included systematic reviews, clinical trials, and observational studies (cohort and case-control) that reported utility outcomes using validated instruments such as SF-6D, MG-QOL15, and EQ-5D. Risk of bias was assessed using ROBINS-I V2, while the certainty of evidence was evaluated via the GRADE framework.

Results

Of the 334 records identified, four were included in the systematic review. One study had a cross-sectional cohort design, while the remaining three were prospective cohort studies. Available utility values were stratified according to several factors, including disease severity, age, sex, comorbidities, and housing conditions; however, no utility estimates stratified by pharmacological treatment were identified. Based on the available evidence and considering its applicability to the Brazilian context, a mean utility value of 0.761 was selected for individuals with MG, corresponding to an absolute utility decrement of 0.089 compared with population norms. The evidence was assessed with a serious risk of bias and a low certainty of the evidence.

Conclusions

Although evidence on utility values in MG remains limited and heterogeneous, the findings of this systematic review provide essential data to inform future economic evaluations in Brazil. The selected utility value supports the development of cost–utility models and may contribute to more robust and accurate health technology assessments for MG.

Zitieren

APA

Santos, M., Costa, M. G. S. D., Yoshida, L. F., Kanevsky, G. A., & Coelho, L. T. E. R. (2026). Health utility values in myasthenia gravis: a systematic review of health-related quality of life evidence and estimations for Brazilian economic models. HTA Journal, 1(1), 19-31. https://doi.org/10.67516/htaj.26.1.19

Vancouver

Santos M, Costa MGSD, Yoshida LF, Kanevsky GA, Coelho LTER. Health utility values in myasthenia gravis: a systematic review of health-related quality of life evidence and estimations for Brazilian economic models. HTA Journal. 2026;1(1):19-31. doi:10.67516/htaj.26.1.19

BibTeX
@article{Santos2026,
  author = {Santos, Marisa and Costa, Márcia Gisele Santos da and Yoshida, Ligia Fernande and Kanevsky, Gabriela Ana and Coelho, Ligia Taveira Engler Raiz},
  title = {Health utility values in myasthenia gravis: a systematic review of health-related quality of life evidence and estimations for Brazilian economic models},
  journal = {HTA Journal},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {19--31},
  doi = {10.67516/htaj.26.1.19}
}
Kostenlos starten →